Search

Your search keyword '"Schnetzler, Gabriel"' showing total 43 results
Start Over Author "Schnetzler, Gabriel"
43 results on '"Schnetzler, Gabriel"'

1. Optimizing Early Clinical Investigations in Cancer Immunotherapy: The Translational Journey of RG6292, a Novel, Selective Treg‐Depleting Antibody

Author

Belli, Sara, primary, Amann, Maria, additional, Hutchinson, Lucy, additional, Pousse, Laurène, additional, Abdolzade‐Bavil, Afsaneh, additional, Justies, Nicole, additional, Jacobsen, Bjoern, additional, Ploix, Corinne, additional, Tselempi, Eleni, additional, Tosevski, Vinko, additional, Koll, Hans, additional, Schnetzler, Gabriel, additional, Boetsch, Christophe, additional, and Marrer‐Berger, Estelle, additional

Published
2024
Full Text
View/download PDF

2. Abstract CT176: Pharmacokinetic/pharmacodynamic (PK/PD) relationships of the novel Treg depleter RG6292 in Phase Ia and Ib studies in patients with solid tumors

Author

Tanos, Tamara, primary, Smart, Kevin, additional, Gambardella, Valentina, additional, Rohrberg, Kristoffer, additional, Ong, Michael, additional, Rodriguez Ruiz, Maria Esperanza, additional, Machiels, Jean-Pascal, additional, Sanmamed, Miguel Fernández, additional, Tabernero, Josep, additional, Spreafico, Anna, additional, Renouf, Daniel, additional, Luen, Stephen, additional, Galot, Rachel, additional, Doger, Bernard, additional, Calvo, Emiliano, additional, Naing, Aung, additional, Curdt, Samira, additional, Staedler, Nicolas, additional, Flores, Mike, additional, Alcaide, Enrique Gómez, additional, Ooi, Chiahuey, additional, Hettich, Michael, additional, Dziadek, Sebastian, additional, Xie, Yuying, additional, Schnetzler, Gabriel, additional, Kolben, Theresa, additional, Xu, Linxinyu, additional, Karanikas, Vaios, additional, and Boetsch, Christophe, additional

Published
2023
Full Text
View/download PDF

3. Abstract CT110: Safety and anti-tumor activity of a novel Treg depleter RG6292, as a single agent and in combination with atezolizumab in patients with solid tumors

Author

Gambardella, Valentina, primary, Ong, Michael, additional, Ruiz, Maria Esperanza Rodriguez, additional, Machiels, Jean-Pascal, additional, de Sanmamed, Miguel Fernandez, additional, Tabernero, Josep Maria, additional, Spreafico, Anna, additional, Renouf, Daniel J, additional, Luen, Stephen J, additional, Galot, Rachel, additional, de Speville Uribe, Bernard Doger, additional, Aller, Emiliano Calvo, additional, Naing, Aung, additional, Curdt, Samira, additional, Rossmann, Eva, additional, Tanos, Tamara, additional, Smart, Kevin, additional, Amann, Maria, additional, Xie, Yuying, additional, Schnetzler, Gabriel, additional, Boetsch, Christophe, additional, Karanikas, Vaios, additional, Kolben, Theresa, additional, Xu, Linxinyu, additional, and Rohrberg, Kristoffer S, additional

Published
2023
Full Text
View/download PDF

4. Data from Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis

Author

Bonfill-Teixidor, Ester, primary, Iurlaro, Raffaella, primary, Handl, Cornelia, primary, Wichmann, Jürgen, primary, Arias, Alexandra, primary, Cuartas, Isabel, primary, Emmenegger, Jasmin, primary, Romagnani, Andrea, primary, Mangano, Luca, primary, Lorber, Thomas, primary, Berrera, Marco, primary, Godfried Sie, Christina, primary, Köchl, Fabian, primary, Eckmann, Jan, primary, Feddersen, Romi, primary, Kornacker, Martin, primary, Schnetzler, Gabriel, primary, Cicuendez, Marta, primary, Cordero, Esteban, primary, Topczewski, Thomaz E., primary, Ferres-Pijoan, Abel, primary, González, Josep, primary, Martínez-Ricarte, Francisco, primary, Muñoz-Couselo, Eva, primary, Tabernero, Josep, primary, Bischoff, James R., primary, Pettazzoni, Piergiorgio, primary, and Seoane, Joan, primary

Published
2023
Full Text
View/download PDF

5. Supplementary Table from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor

Author

Wichmann, Jürgen, primary, Rynn, Caroline, primary, Friess, Thomas, primary, Petrig-Schaffland, Jeannine, primary, Kornacker, Martin, primary, Handl, Cornelia, primary, Emmenegger, Jasmin, primary, Eckmann, Jan, primary, Herting, Frank, primary, Frances, Nicolas, primary, Hunziker, Daniel, primary, Krummenacher, Daniela, primary, Rüttinger, Dominik, primary, Ribeiro, Alison, primary, Bacac, Marina, primary, Brigo, Alessandro, primary, Hewings, David S., primary, Dummer, Reinhard, primary, Levesque, Mitchell P., primary, Schnetzler, Gabriel, primary, Martoglio, Bruno, primary, Bischoff, James R., primary, and Pettazzoni, Piergiorgio, primary

Published
2023
Full Text
View/download PDF

6. Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor

Author

Wichmann, Jürgen, primary, Rynn, Caroline, primary, Friess, Thomas, primary, Petrig-Schaffland, Jeannine, primary, Kornacker, Martin, primary, Handl, Cornelia, primary, Emmenegger, Jasmin, primary, Eckmann, Jan, primary, Herting, Frank, primary, Frances, Nicolas, primary, Hunziker, Daniel, primary, Krummenacher, Daniela, primary, Rüttinger, Dominik, primary, Ribeiro, Alison, primary, Bacac, Marina, primary, Brigo, Alessandro, primary, Hewings, David S., primary, Dummer, Reinhard, primary, Levesque, Mitchell P., primary, Schnetzler, Gabriel, primary, Martoglio, Bruno, primary, Bischoff, James R., primary, and Pettazzoni, Piergiorgio, primary

Published
2023
Full Text
View/download PDF

7. Supplementary Data from Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis

Author

Bonfill-Teixidor, Ester, primary, Iurlaro, Raffaella, primary, Handl, Cornelia, primary, Wichmann, Jürgen, primary, Arias, Alexandra, primary, Cuartas, Isabel, primary, Emmenegger, Jasmin, primary, Romagnani, Andrea, primary, Mangano, Luca, primary, Lorber, Thomas, primary, Berrera, Marco, primary, Godfried Sie, Christina, primary, Köchl, Fabian, primary, Eckmann, Jan, primary, Feddersen, Romi, primary, Kornacker, Martin, primary, Schnetzler, Gabriel, primary, Cicuendez, Marta, primary, Cordero, Esteban, primary, Topczewski, Thomaz E., primary, Ferres-Pijoan, Abel, primary, González, Josep, primary, Martínez-Ricarte, Francisco, primary, Muñoz-Couselo, Eva, primary, Tabernero, Josep, primary, Bischoff, James R., primary, Pettazzoni, Piergiorgio, primary, and Seoane, Joan, primary

Published
2023
Full Text
View/download PDF

8. Activity and resistance of a brain-permeable paradox breaker BRAF inhibitor in melanoma brain metastasis

Author

Bonfill-Teixidor, Ester, primary, Iurlaro, Raffaella, additional, Handl, Cornelia, additional, Wichmann, Jürgen, additional, Arias, Alexandra, additional, Cuartas, Isabel, additional, Emmenegger, Jasmin, additional, Romagnani, Andrea, additional, Mangano, Luca, additional, Lorber, Thomas, additional, Berrera, Marco, additional, Godfried Sie, Christina, additional, Köchl, Fabian, additional, Eckmann, Jan, additional, Feddersen, Romi, additional, Kornacker, Martin, additional, Schnetzler, Gabriel, additional, Cicuéndez, Marta, additional, Cordero, Esteban, additional, Topczewski, Thomaz E., additional, Ferrés-Pijoan, Abel, additional, Gonzalez, Josep, additional, Martínez-Ricarte, Francisco, additional, Muñoz-Couselo, Eva, additional, Tabernero, Josep, additional, Bischoff, James R., additional, Pettazzoni, Piergiorgio, additional, and Seoane, Joan, additional

Published
2022
Full Text
View/download PDF

11. Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor

Author

Wichmann, Jürgen, primary, Rynn, Caroline, additional, Friess, Thomas, additional, Petrig-Schaffland, Jeannine, additional, Kornacker, Martin, additional, Handl, Cornelia, additional, Emmenegger, Jasmin, additional, Eckmann, Jan, additional, Herting, Frank, additional, Frances, Nicolas, additional, Hunziker, Daniel, additional, Krummenacher, Daniela, additional, Rüttinger, Dominik, additional, Ribeiro, Alison, additional, Bacac, Marina, additional, Brigo, Alessandro, additional, Hewings, David S., additional, Dummer, Reinhard, additional, Levesque, Mitchell P., additional, Schnetzler, Gabriel, additional, Martoglio, Bruno, additional, Bischoff, James R., additional, and Pettazzoni, Piergiorgio, additional

Published
2021
Full Text
View/download PDF

20. Vismodegib (ERIVEDGE) pregnancy prevention programme: assessment of risk awareness.

Author

Schnetzler, Gabriel, Cuberos, Miguel, Bucher, Reinhard, Stassen, Katja, and Mingrino, Roberto

Subjects
*RISK perception, *BIRTH control, *VISMODEGIB, *RISK assessment, *BASAL cell carcinoma, *INAPPROPRIATE prescribing (Medicine)
Abstract

Vismodegib (Erivedge; Roche), a Hedgehog pathway inhibitor (HPI), is indicated for the treatment of symptomatic metastatic basal cell carcinoma (BCC) and locally advanced BCC inappropriate for surgery or radiotherapy. Due to the known risk of HPI teratogenicity, the Erivedge Pregnancy Prevention Program (PPP) was introduced at approval (2013) as part of the EU Risk Management Plan. Structured, quantitative Web-based surveys were conducted in 2015 (Wave 1), 2016 (Wave 2), and 2017/2018 (Wave 3) among prescribing oncologists and dermato-oncologists in Austria, France, Germany, Hungary, and the United Kingdom to assess the effectiveness of the Erivedge PPP. Overall, 95%, 87%, and 91% of respondents in Waves 3 (N = 181), 2 (N = 214), and 1 (N = 207), respectively, were vismodegib prescribers. The surveys consistently showed a high awareness about the risk of teratogenicity associated with vismodegib (98%, Wave 3; 95%, Wave 2) and that a high proportion of prescribing physicians took appropriate precautions to minimize this risk (95%, Wave 3; 92%, Wave 2; 88%, Wave 1). Physicians were also highly aware of the Erivedge PPP (70%, Wave 3; 67%, Wave 2; 71%, Wave 1). Survey data suggest that the risk of teratogenicity with vismodegib has been effectively communicated to the prescribing community. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

23. Abstract 4553: The CD25 antibody RG6292 selectively depletes Tregs while preserving IL-2 signaling and CTL activity for tumor control

Author

Amann, Maria, primary, Schnetzler, Gabriel, additional, Theresa, Kolben, additional, Solomon, Isabelle, additional, Boetsch, Christophe, additional, Marrer-Berger, Estelle, additional, Flury, Reto, additional, Murgia, Claudio, additional, Karanikas, Vaios, additional, Sam, Johannes, additional, Sutmuller, Roger, additional, Eckmann, Jan, additional, Koll, Hans, additional, Belli, Sara, additional, Vargas, Frederic Arce, additional, Zervas, Dimitrios, additional, Qing, Chen, additional, Brown, Mark A., additional, Salimu, Josephine, additional, Goubier, Anne, additional, Neumann, Sebastian, additional, Peggs, Karl S., additional, and Quezada, Sergio A., additional

Published
2020
Full Text
View/download PDF

26. Model‐based approach for methoxy polyethylene glycol‐epoetin beta drug development in paediatric patients with anaemia of chronic kidney disease

Author

Chanu, Pascal, primary, Schaefer, Franz, additional, Warady, Bradley A., additional, Schmitt, Claus Peter, additional, Reigner, Bruno, additional, Schnetzler, Gabriel, additional, Meyer Reigner, Sylvie, additional, Eisner, Mark, additional, Weichert, Arlette, additional, and Frey, Nicolas, additional

Published
2020
Full Text
View/download PDF

31. Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Author

Hutchings, Martin, Montesinos, Pau, Santoro, Armando, Hou, Hsin-An, Martinez-Sanchez, Maria Pilar, Vives, Susana, Galimberti, Sara, Chen, Tsai-Yun, Frigeni, Marco, Garciaz, Sylvain, Salamero, Olga, Yeh, Su-Peng, Yee, Karen, Schnetzler, Gabriel, Barata, Teresa, Simon, Silke, Hinton, Heather, Korfi, Koorosh, Richard, Muriel, Keshelava, Nino, and Subklewe, Marion

Abstract

Background: RO7283420 (RG6007) is a 2+1 TCR-like (TCR-L) T-cell bispecific (TCB) antibody targeting CD3 and the RMFPNAPYL peptide of Wilms Tumor 1 (WT1) protein presented by the major histocompatibility complex-I HLA-A*02 on acute myeloid leukemia (AML) blasts and other antigen presenting cells. The pre-clinical evaluation of RO7283420 in our in vivohumanized AML xenografts and ex vivoAML co-culture models showed strong T-cell mediated AML cell killing (Augsberger C, et al. Blood2021). A Phase 1 dose-escalation (DE) study (NCT04580121) evaluated the safety, tolerability, pharmacokinetics, anti-drug antibodies (ADAs), and anti-leukemic activity of RO7283420 in patients with relapsed/refractory (R/R) AML.

Published
2023
Full Text
View/download PDF

32. Malaria chemoprophylaxis regimens: A descriptive drug utilization study

Author

Bloechliger, Marlene, Schlagenhauf, Patricia, Toovey, Stephen, Schnetzler, Gabriel, Tatt, Iain, Tomianovic, Danitza, Jick, Susan S, Meier, Christoph R, University of Zurich, and Meier, Christoph R

Subjects
610 Medicine & health, 10060 Epidemiology, Biostatistics and Prevention Institute (EBPI), 2739 Public Health, Environmental and Occupational Health, 2725 Infectious Diseases
Published
2014

34. Estudio EPIFARM

Author

Martín Morales, Antonio, Ibáñez, José, Machuca, Manuel, Pol-Yanguas, Emilio, Schnetzler, Gabriel, and Pascual Renedo, Virginia

Subjects
Disfunción eréctil, iPDE5, farmacéutico, medicamento de dispensación con receta, medicamento de dispensación sin receta
Abstract

INTRODUCCIÓN Los farmacéuticos comunitarios pueden ser un importante primer punto de contacto con los pacientes con disfunción eréctil (DE), pero hasta la fecha no hay ningún estudio sobre las características de los hombres que acuden a un farmacéutico solicitando consejo o tratamiento para la DE.OBJETIVO Caracterizar los perfiles de los hombres que solicitan tratamiento para la DE en la farmacia, con o sin receta de inhibidores de la fosfodiesterasa tipo 5 (iPDE5).MÉTODOS Entre septiembre y noviembre de 2008 se realizó un estudio observacional, transversal y multicéntrico en farmacias comunitarias de España. De aquellos hombres que solicitaban consejo o tratamiento para la DE, cada investigador reclutó un paciente que tenía receta médica de iPDE5 y otro que acudía sin receta médica. Los farmacéuticos del estudio completaron un cuestionario de datos demográficos, clínicos y conductuales del paciente, incluido el Cuestionario de salud sexual para varones (Sexual Health Inventory for Men).VARIABLES PRINCIPALES Características demográficas y respuestas a los cuestionarios.RESULTADOS 574 farmacéuticos seleccionaron a 1.147 pacientes, de los cuales 1.113 fueron incluidos en el análisis. No se observaron diferencias estadísticas entre los grupos en cuanto al peso, la hipertensión, la diabetes mellitus, la hipercolesterolemia, la dislipidemia, la depresión o el estrés. Tampoco se observaron diferencias estadísticas respecto a la gravedad de la DE (p = 0,7892) ni a la proporción de hombres sin DE en cada grupo (p = 0,5755). En ambos grupos, los pacientes habían presentado síntomas de DE durante una media de veintiséis meses antes de la primera consulta a un profesional sanitario. Para el 60,2% de los pacientes incluidos en el grupo sin receta, la visita a la farmacia fue la primera ocasión en la que habían hablado de su DE con un profesional sanitario, y el 50% de aquellos que habían hablado previamente de la DE lo habían hecho en primer lugar con un farmacéutico. En este grupo de pacientes sin receta, el 85,1% de los hombres solicitaba un iPDE5.CONCLUSIONES Muchos hombres acuden a un farmacéutico comunitario buscando tratamiento para la DE, y los pacientes con receta médica de un iPDE5 presentan un perfil de gravedad de la disfunción eréctil y de comorbilidades equivalente al de aquellos pacientes que no presentan receta. Los farmacéuticos comunitarios deberían recibir formación sobre los criterios actuales de diagnóstico y tratamiento de la DE, para poder informar a los hombres y animarles a acudir al médico, lo que aumentaría la probabilidad de detección precoz de comorbilidades no diagnosticadas, como la enfermedad cardiovascular. Martín Morales A, Ibáñez J,MachucaM, Pol-Yanguas E, Schnetzler G y Renedo VP. Pharmacies in Spain characterizing patient profiles of men asking for erectile dysfunction medication. J SexMed 2010;7:3153-3160.

Published
2010

39. Pharmaceutical quality of eight generics of ceftriaxone preparation for injection in Eastern Asia

Author

Arnet, Isabelle, Altermatt, Matthias, Roggo, Yves, and Schnetzler, Gabriel

Abstract

Objectives:To compare the pharmaceutical quality of original and generic ceftriaxone sodium preparations for injection produced in Eastern Asia.Methods:Standard physical and chemical laboratory tests were performed.Participants/material:Ceftriaxone (Rocephin®, Roche, Switzerland) was the reference material. Generics produced in China, India, and Indonesia were sampled in China and Myanmar within their expiration dates.Results:Eight generics obtained from Eastern Asia markets in January 2013 were analysed. All eight generics failed the specifications in three or more tests. Residues of solvents and metals were detected in all generics, four were not particle free, and two were not sterile.Conclusions:All tested generic ceftriaxone products failed to meet the pharmaceutical quality standards of the branded original. The high levels of impurities and the identified contamination of particles and residues are of clinical concern, as they could impact tolerability and safety in patients in need of an effective parenteral antibiotic.

Published
2015
Full Text
View/download PDF

41. Induction of the IL-10 gene via the Fas receptor in monocytes – an anti-inflammatory mechanism in the absence of apoptosis

Author

Daigle, Isabelle, Rückert, Beate, Schnetzler, Gabriel, and Simon, Hans-Uwe

Abstract

Death receptors play an important role in controlling cell numbers and immune responses. In contrast to TNF receptors, little is known about non-apoptosis functions of the Fas receptor (CD95, APO-1). Here we demonstrate that Fas receptor engagement results in the induction of the IL-10 gene in monocytes, but not in lymphocytes or dendritic cells. In contrast, TNF-α stimulated IL-10 production in dendritic cells but not monocytes. Fas receptor-mediated transcriptional activation of the IL-10 gene was followed by the release of large amounts of the cytokine in cell cultures and occurred in the absence of apoptosis induction. Since caspase activation did not occur in monocytes following Fas receptor engagement, it is unlikely that caspases are involved in IL-10 gene activation. Monocyte-derived IL-10 suppressed T cell proliferation induced by anti-CD3 monoclonal antibody without affecting CD3-mediated transmembrane signal transduction. In conclusion, we report about a novel pathway initiated via the Fas receptor leading to transcriptional activation of at least one cytokine gene. Fas ligand-induced IL-10 production in monocytes might represent an important anti-inflammatory mechanism in secondary immune responses.

Published
2000
Full Text
View/download PDF

42. Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor.

Author

Wichmann J, Rynn C, Friess T, Petrig-Schaffland J, Kornacker M, Handl C, Emmenegger J, Eckmann J, Herting F, Frances N, Hunziker D, Krummenacher D, Rüttinger D, Ribeiro A, Bacac M, Brigo A, Hewings DS, Dummer R, Levesque MP, Schnetzler G, Martoglio B, Bischoff JR, and Pettazzoni P

Subjects
Brain pathology, Cell Line, Tumor, Drug Resistance, Neoplasm, Humans, Molecular Targeted Therapy, Protein Kinase Inhibitors pharmacology, Protein Kinase Inhibitors therapeutic use, Melanoma drug therapy, Melanoma genetics, Melanoma pathology, Proto-Oncogene Proteins B-raf
Abstract

Purpose: Disease progression in BRAF V600E/K positive melanomas to approved BRAF/MEK inhibitor therapies is associated with the development of resistance mediated by RAF dimer inducing mechanisms. Moreover, progressing disease after BRAFi/MEKi frequently involves brain metastasis. Here we present the development of a novel BRAF inhibitor (Compound Ia) designed to address the limitations of available BRAFi/MEKi., Experimental Design: The novel, brain penetrant, paradox breaker BRAFi is comprehensively characterized in vitro, ex vivo, and in several preclinical in vivo models of melanoma mimicking peripheral disease, brain metastatic disease, and acquired resistance to first-generation BRAFi., Results: Compound Ia manifested elevated potency and selectivity, which triggered cytotoxic activity restricted to BRAF-mutated models and did not induce RAF paradoxical activation. In comparison to approved BRAFi at clinical relevant doses, this novel agent showed a substantially improved activity in a number of diverse BRAF V600E models. In addition, as a single agent, it outperformed a currently approved BRAFi/MEKi combination in a model of acquired resistance to clinically available BRAFi. Compound Ia presents high central nervous system (CNS) penetration and triggered evident superiority over approved BRAFi in a macro-metastatic and in a disseminated micro-metastatic brain model. Potent inhibition of MAPK by Compound Ia was also demonstrated in patient-derived tumor samples., Conclusions: The novel BRAFi demonstrates preclinically the potential to outperform available targeted therapies for the treatment of BRAF-mutant tumors, thus supporting its clinical investigation., (©2021 American Association for Cancer Research.)

Published
2022
Full Text
View/download PDF

43. Invasive aspergillosis: is treatment with "inexpensive" amphotericin B cost saving if "expensive" voriconazole is only used on demand?

Author

Garbino J, Schnetzler G, and Roberts C

Subjects
Acute Kidney Injury etiology, Amphotericin B adverse effects, Amphotericin B economics, Antifungal Agents economics, Aspergillosis economics, Cost-Benefit Analysis, Decision Trees, Humans, Models, Economic, Pyrimidines therapeutic use, Triazoles therapeutic use, Voriconazole, Acute Kidney Injury economics, Amphotericin B therapeutic use, Antifungal Agents therapeutic use, Aspergillosis drug therapy, Pyrimidines economics, Triazoles economics
Abstract

Background: Voriconazole for the treatment of invasive aspergillosis (IA) shows superior clinical outcome and tolerability compared to conventional amphotericin B. However, the latter is often used as initial treatment due to lower drug acquisition costs. Therefore we performed a cost-effectiveness analysis., Methods: A decision analytic model was designed to compare the cost-effectiveness of a regimen of voriconazole followed by conventional amphotericin B to a regimen of conventional amphotericin B followed by voriconazole. Patients initiated on treatment either completed initial therapy or switched to second line therapy due to toxicity or non-response. Probability of a switch was based on clinical trial data and local rates of renal toxicity. Resource use in the hospital was taken from the Global Comparative Aspergillosis (GCA) study. Costs were based on local drug acquisition costs, local cost estimates for hospitalisation and adjusted additional costs of amphotericin B-induced acute renal failure from the literature. Effectiveness was defined as survival at 12 weeks from the GCA study. An incremental cost-effectiveness ratio was estimated as the incremental cost per life saved comparing voriconazole to conventional amphotericin B., Results: Based on this model, initial therapy of IA with voriconazole reduced total costs when compared to initial therapy with conventional amphotericin B (CHF 37 878/patient vs CHF 49 861/patient) and resulted in better survival at 12 weeks, making it the dominant treatment in terms of incremental cost-effectiveness. Results were most sensitive to alternative assumptions of the incidence of acute renal failure, but cost savings were sustained for voriconazole over a wide range of values., Conclusion: Considering that initial therapy with voriconazole is both cost-saving and results in better clinical outcomes, voriconazole is the dominant cost-effective option for initial therapy of IA, despite very low drug acquisition costs of conventional amphotericin B.

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results